TiumBio Statistics
Total Valuation
TiumBio has a market cap or net worth of KRW 178.88 billion. The enterprise value is 176.11 billion.
| Market Cap | 178.88B |
| Enterprise Value | 176.11B |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TiumBio has 27.14 million shares outstanding. The number of shares has increased by 11.99% in one year.
| Current Share Class | 27.14M |
| Shares Outstanding | 27.14M |
| Shares Change (YoY) | +11.99% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 36.09% |
| Owned by Institutions (%) | 0.04% |
| Float | 17.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.39 |
| PB Ratio | 3.30 |
| P/TBV Ratio | 4.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.79 |
| EV / Sales | 24.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -13.02 |
Financial Position
The company has a current ratio of 2.16, with a Debt / Equity ratio of 0.68.
| Current Ratio | 2.16 |
| Quick Ratio | 1.88 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.74 |
| Interest Coverage | -4.08 |
Financial Efficiency
Return on equity (ROE) is -21.68% and return on invested capital (ROIC) is -12.79%.
| Return on Equity (ROE) | -21.68% |
| Return on Assets (ROA) | -11.04% |
| Return on Invested Capital (ROIC) | -12.79% |
| Return on Capital Employed (ROCE) | -22.77% |
| Revenue Per Employee | 107.85M |
| Profits Per Employee | -154.27M |
| Employee Count | 68 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +51.23% in the last 52 weeks. The beta is 0.65, so TiumBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +51.23% |
| 50-Day Moving Average | 6,386.60 |
| 200-Day Moving Average | 4,991.05 |
| Relative Strength Index (RSI) | 45.43 |
| Average Volume (20 Days) | 561,406 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TiumBio had revenue of KRW 7.33 billion and -10.49 billion in losses. Loss per share was -397.77.
| Revenue | 7.33B |
| Gross Profit | 6.68B |
| Operating Income | -18.44B |
| Pretax Income | -12.55B |
| Net Income | -10.49B |
| EBITDA | -14.79B |
| EBIT | -18.44B |
| Loss Per Share | -397.77 |
Balance Sheet
The company has 51.25 billion in cash and 37.06 billion in debt, giving a net cash position of 14.19 billion or 522.62 per share.
| Cash & Cash Equivalents | 51.25B |
| Total Debt | 37.06B |
| Net Cash | 14.19B |
| Net Cash Per Share | 522.62 |
| Equity (Book Value) | 54.15B |
| Book Value Per Share | 1,581.34 |
| Working Capital | 32.55B |
Cash Flow
In the last 12 months, operating cash flow was -13.41 billion and capital expenditures -118.65 million, giving a free cash flow of -13.53 billion.
| Operating Cash Flow | -13.41B |
| Capital Expenditures | -118.65M |
| Free Cash Flow | -13.53B |
| FCF Per Share | -498.31 |
Margins
Gross margin is 91.10%, with operating and profit margins of -251.41% and -143.04%.
| Gross Margin | 91.10% |
| Operating Margin | -251.41% |
| Pretax Margin | -171.18% |
| Profit Margin | -143.04% |
| EBITDA Margin | -201.63% |
| EBIT Margin | -251.41% |
| FCF Margin | n/a |
Dividends & Yields
TiumBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.99% |
| Shareholder Yield | -11.99% |
| Earnings Yield | -5.86% |
| FCF Yield | -7.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TiumBio has an Altman Z-Score of 0.96 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.96 |
| Piotroski F-Score | 2 |